Moderna's management focuses on oncology and rare diseases, reducing reliance on respiratory vaccines. Goldman Sachs estimates Moderna will break even at ~$6 billion in revenue by 2028.
Jefferies analysts said Investor sentiment around Moderna Inc could be nearing a short-term low, amid recent concerns tied to vaccine transparency and structural issues might start to ease.
Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...